In a significant reversal from the prior quarter, Steve Cohen's Point72 Asset Management reduced its stake in medical device maker Boston Scientific (BSX) by 90.09%. According to required quarterly disclosures, the firm's holding dropped from 3.69 million shares to just 365,240. This disclosure, filed on August 14, 2026, reflects trades made during the second quarter, which ended June 30, 2026.
The move is particularly noteworthy as Point72 had dramatically increased its position in BSX during the first quarter of 2026. The sale occurred during a period where Boston Scientific announced a major global restructuring plan in late July and had previously slashed its 2026 guidance in April. As 13F filings are delayed, they represent a past position and may not reflect the firm's current holdings.